ArticleFrontiers in neurology2025
Effect of hyperbaric oxygen therapy on peripheral blood inflammatory markers in patients with neuromyelitis optica spectrum disorder: a retrospective cohort study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuromyelitis optica spectrum disorder (NMOSD), an AQP4-IgG-mediated central nervous system demyelinating disease, is prone to recurrent disability. Although the anti-inflammatory and neuroprotective effects of hyperbaric oxygen therapy (HBOT) in neurological diseases have been reported, its immunological impact on NMOSD remains poorly understood. Objective: To evaluate the effect of HBOT on peripheral inflammatory markers in patients with NMOSD and explore its potential immunomodulatory role. Methods: This retrospective cohort study included 36 NMOSD patients diagnosed between January 2022 and December 2024, divided into an HBOT plus standard treatment group ( Results: After a median of 12 HBOT sessions, the HBOT group showed a 31.78% increase in lymphocyte count (Δ = +0.41 × 10 Conclusion: HBOT may help rebalance the immune system in NMOSD by increasing lymphocyte counts and reducing NLR and PLR, potentially contributing to immune modulation. These findings support the potential of HBOT as an adjunctive therapy for NMOSD, particularly in patients with a high inflammatory burden. Larger prospective studies are warranted to confirm its long-term efficacy and underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.